Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹258.85down ₹5.35 (2.03%)BSE ₹258.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹264.20.
30 Oct: open ₹263.50, high ₹265.65, low ₹257.00
52-week range of traded prices to 30 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,314 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,67850.0% delivered
Suven Life Sciences analyst meets
28 filed, newest first.
Jul 2026
14 Jul · Analysts
Feb 2020
11 Feb · Analysts
Nov 2019
11 Nov · Analysts
Aug 2019
7 Aug · Analysts
May 2019
27 May · Analysts
22 May · Analysts
Feb 2019
8 Feb · Analysts
Jan 2019
31 Jan · Analysts
Nov 2018
30 Nov · Analysts
9 Nov · Analysts
Aug 2018
8 Aug · Analysts
May 2018
10 May · Analysts
Jan 2018
25 Jan · Analysts
Dec 2017
11 Dec · Analysts
Nov 2017
8 Nov · Analysts
Aug 2017
11 Aug · Analysts
Jun 2017
1 Jun · Analysts
May 2017
30 May · Analysts
11 May · Analysts
Feb 2017
3 Feb · Analysts
Jan 2017
30 Jan · Analysts
Nov 2016
24 Nov · Analysts
22 Nov · Analysts
Aug 2016
May 2016
27 May · Analysts
Mar 2016